deCODE believes the test will be useful for better predicting risk of prostate cancer, helping to optimize both screening and treatment. deCODE PrCa detects a total of six previously discovered SNPs that have been confirmed in many populations, as well as two SNPs on chromosomes X and 2 that were reported by deCODE scientists.
Kari Stefansson, CEO of decode, said: “Through deCODE PrCa, we are bringing together in one tool all of the major genetic risk factors for prostate cancer that we have discovered over the past eighteen months. We believe that this is a test with significant clinical utility for improving and personalizing the screening and treatment of one of the most common cancers.”